About WELIREG®▼ (belzutifan)
How WELIREG works
WELIREG is a first-in-class HIF-2α inhibitor, which may reduce the transcription of genes that drive tumour growth in VHL disease.
Dosing for WELIREG
Information on dosing, including
recommended dose reductions and dose modifications for adverse reactions.
Formulary Support Pack
Formulary application support pack to support you in the completion of a formulary application for WELIREG.
NICE Recommendation
WELIREG is recommended with managed access,
as an option for treating VHL disease in adults who need treatment for VHL-associated RCC, CNS hemangioblastomas or pNET tumours, and when localised procedures are unsuitable or undesirable.3
SMC Acceptance
WELIREG is accepted within its indication,
for the treatment of adult patients with VHL disease who require therapy for VHL associated RCC, CNS hemangioblastomas, or pNET, and for whom localised procedures are unsuitable or undesirable.4
Stay up to date with the latest on WELIREG
Receive data updates, resources and invites to meetings and events
References
- Narayan V, Jonasch E. Systemic therapy development in von Hippel-Lindau disease: an outsized contribution from an orphan disease. Cancers (Basel). 2022;14(21):5313.
- Gov.uk Press Release. First Innovation Passport awarded to help support development and access to cutting-edge medicines. Available at: https://www.gov.uk/ government/news/first-innovation-passport-awarded-to-help-support-development-and-access-to-cutting-edge-medicines. Accessed: January 2025.
- NICE. Belzutifan for treating tumours associated with von Hippel-Lindau disease. Available at: https://www.nice.org.uk/guidance/ta1011/chapter/1-Recommendations. Accessed: January 2025.
- SMC. 2023. Belzutifan (Welireg). Available at: https://www.scottishmedicines.org.uk/medicines-advice/belzutifan-welireg-full-smc2587/. Accessed: January 2025.
- WELIREG Summary of Product Characteristics.
Indication
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
